Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
For a study published in Molecular Cell this month, researchers at Tsinghua University tested and compared three droplet-based single-cell RNA sequencing methods.
